Trial Profile
A blinded randomised multicentre study to evaluate fixed dose single administration filgrastim-SD/01 vs daily filgrastim as an adjuvant to chemotherapy stage II or III/IV breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 24 Feb 2006 New trial record.